Publicacións en colaboración con investigadores/as de Barcelona Institute for Science and Technology (10)

2021

  1. Comparison of covid‐19 and non‐covid‐19 pneumonia in down syndrome

    Journal of Clinical Medicine, Vol. 10, Núm. 16

  2. Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

    Clinical Nutrition, Vol. 39, Núm. 2, pp. 378-387

  2. Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management

    Clinical Nutrition, Vol. 39, Núm. 4, pp. 1292-1300

  3. Molecular rescue of DYRK1A overexpression alterations in mice with fontup® dietary supplement: Role of green tea catechins

    International Journal of Molecular Sciences, Vol. 21, Núm. 4

2019

  1. Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome

    Neurobiology of Disease, Vol. 125, pp. 92-106

  2. Metabolomics predicts the pharmacological profile of new psychoactive substances

    Journal of Psychopharmacology, Vol. 33, Núm. 3, pp. 347-354

2018

  1. Translating molecular advances in Down syndrome and Fragile X syndrome into therapies

    European Neuropsychopharmacology, Vol. 28, Núm. 6, pp. 675-690

2016

  1. VNTR-DAT1 and COMTVal158Met genotypes modulate mental flexibility and adaptive behavior skills in down syndrome

    Frontiers in Behavioral Neuroscience, Vol. 10, Núm. OCT

2015

  1. Semantic verbal fluency pattern, dementia rating scores and adaptive behavior correlate with plasma Aβ42concentrations in down syndrome young adults

    Frontiers in Behavioral Neuroscience, Vol. 9, Núm. NOVEMBER